News


RTI Surgical® Announces Commercial Launch of the CervAlign® Anterior Cervical Plate System

Molly Poarch
Investor Contact
mpoarch@rtix.com
+1 224 287 2661

Steven Cohen
Media Contact
scohen@rtix.com
+1 847 648 0861

RTI expands its Established Therapies spine portfolio to further meet surgeon and patient needs

Deerfield, Ill. – September 24, 2019 – RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, today announced the full commercial launch of the CervAlign® Anterior Cervical Plate (ACP) System to add to the growth of its Established Therapies spine portfolio.

The CervAlign ACP System is designed to promote cervical fusion by providing temporary resistance to flexion, extension, lateral bending and axial rotation with strength and stiffness in the cervical spine (C2-C7). The system includes implants of various plate and screw sizes to accommodate varying patient anatomies. It also helps reduce complexity for the surgeon customer with an integrated cover-style locking mechanism that adds zero profile, streamlined instrumentation with the same driver for screws, pins, locking and revisions, and low-profile plates ranging from one to five levels, each with large graft windows for intraoperative visibility. Additionally, using the Fortilink®-C Interbody Fusion (IBF) System with TETRAfuse® 3D Technology and ViBone® Viable Bone Matrix with the CervAlign ACP provides surgeons a complete anterior cervical discectomy and fusion (ACDF) solution.

“The locking mechanism on the CervAlign ACP System is easily visible and engaged, and there is no guesswork as to whether it is completely locked,” said Franco E. Vigna, MD, MPH, FACOS of reVive Spine Center in Buffalo, New York. “Additionally, the amount of screw angulation allows for use of a shorter plate. Combined with the large graft windows and visibility of the plate, it allows surgeons to easily instrument the hard-to-access levels such as C3.”

The CervAlign ACP System is intended for anterior cervical fixation (C2-C7) for the following conditions: degenerative disc disease (DDD) defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies, spondylolisthesis, trauma (e.g., fracture or dislocation), spinal stenosis, deformities or curvatures (e.g., scoliosis, kyphosis, and/or lordosis), tumor, pseudarthrosis and failed previous fusion.

“After a successful Limited Market Release, we are excited to commercially launch the CervAlign ACP system to offer a plate with a cover-style locking mechanism and streamlined instrumentation,” said Camille Farhat, President and CEO. “This is a great example of how we plan to use home-grown innovation to accelerate our spine business. CervAlign ACP adds another option for surgeons in our current Established Therapies portfolio, which we have recently reinvigorated through our R&D efforts across hardware, interbodies and biologics. As we further accelerate growth in spine, we will be able to meet the demands of more surgeons and treat more patients.”

About RTI Surgical Holdings, Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in spine, sports medicine, general surgery, orthopedic and trauma procedures and are distributed in nearly 50 countries. RTI has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, visit www.rtix.com. Connect with us on LinkedIn and Twitter.

Forward-Looking Statements

Portions of this document may constitute “forward-looking statements” as defined by federal law. Although the company believes any such statements are based on reasonable assumptions, there is no assurance that actual outcomes will not be materially different. Any such statements are made in reliance on the “safe harbor” protections provided under the Private Securities Reform Act of 1995. Additional information about issues that could lead to material changes in performance is contained in the company’s annual and quarterly reports filed with the Securities and Exchange Commission.


Contacts

    Molly Poarch
    Director, Corporate Communications
    mpoarch@rtix.com
    +1 224 287 2661

    Steve Cohen
    Manager, Corporate Communications (Spine)
    scohen@rtix.com
    +1 847 648 0861

    Andrea Johnson
    Manager, Corporate Communications (Sports Medicine, OEM, Donor Services & International)
    amjohnson@rtix.com
    +1 630 518 5345

    Jessica Rumschlag
    Executive Assistant, Investor Relations
    jrumschlag@rtix.com
    +1 630 652 5909